Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma. New Data Provide Detail on Trodelv
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks